Novel Werner Syndrome RecQ DNA Helicase (WRN) Inhibitors for Cancer Treatment
The Werner Syndrome RecQ DNA helicase (WRN) plays a crucial role in DNA metabolism and genome stability. This patent collectively demonstrates the synthesis, composition and formulation about novel WRN inhibitors featuring bicyclic heterocycles for cancer treatment.
Authors
- Steven H. Liang (ORCID: https://orcid.org/0000-0003-1413-6315)
- Xin Zhou (ORCID: https://orcid.org/0000-0002-7444-462X)
Institutions
- Georgia Institute of Technology (US)
- Emory University (US)
- The Wallace H. Coulter Department of Biomedical Engineering (US)
Publication Details
- Journal
- ACS Medicinal Chemistry Letters
- Published
- 2026-01-04
- DOI
- https://doi.org/10.1021/acsmedchemlett.5c00746
- Primary Topic
- DNA Repair Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00